What is Invokamet XR, and how does it work?
Invokamet XR, also known as canagliflozin and metformin extended-release, is an oral medication approved for the treatment of type 2 diabetes.[1] It is a combination of two active ingredients: canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin, a biguanide medication.
How does Invokamet XR help control blood sugar levels?
Invokamet XR works by targeting two key mechanisms that contribute to high blood sugar levels in type 2 diabetes patients. Canagliflozin, the SGLT2 inhibitor, blocks the reabsorption of glucose in the kidneys, causing excess glucose to be excreted in the urine. This reduces the amount of glucose in the bloodstream. Metformin, on the other hand, decreases glucose production in the liver and increases insulin sensitivity, allowing glucose to enter the cells more efficiently.
What are the benefits of using Invokamet XR?
Invokamet XR has been shown to improve glycemic control and weight management in patients with type 2 diabetes. It has also been associated with significant reductions in blood pressure and a lower risk of major adverse cardiovascular events, such as heart attack and stroke, compared to other diabetes medications.[2]
Are there any potential side effects or risks associated with Invokamet XR?
As with any medication, Invokamet XR can cause side effects, including vaginal yeast infections, urinary tract infections, and a buildup of lactic acid in the blood (lactic acidosis). It's essential to discuss any concerns or questions with a healthcare provider before starting Invokamet XR.
Can I buy Invokamet XR without a prescription, or is it available as a generic version?
Invokamet XR is only available by prescription and is not currently available as a generic version. However, it's essential to note that generic versions of canagliflozin and metformin are available separately.
When does the patent for Invokamet XR expire, and are biosimilars likely to be approved?
The patent for Invokamet XR is set to expire in 2035, although generic versions may become available earlier through patent challenges or approval of biosimilars.[3] As the patent expiration approaches, companies may face more competition from generic or biosimilar versions of the medication.
References
[1] FDA. (2015). Invokamet XR (canagliflozin and metformin hydrochloride extended-release) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204790s000lbl.pdf
[2] Neal et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644-657. doi: 10.1056/NEJMoa1611902
[3] DrugPatentWatch. (2023). Invokamet XR (canagliflozin and metformin hydrochloride extended-release) tablets. https://www.drugpatentwatch.com/drug/invokamet-xr
Sources:
1. Food and Drug Administration (FDA)
2. Neal et al. (2017)
3. DrugPatentWatch.com